AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01649921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
Study NCT00614861 — intervention group
Intervention type: OTHER
Intervention: Non-cancer pain management survey
Description: Non-cancer pain management survey
Study NCT02795572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU oral once daily
Study NCT02795572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6 100 mg oral once daily
Study NCT03091777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-229
Description: GDC-229 is a vaginal gel.
Study NCT03091777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Vaginal Gel 0.75%
Description: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
Study NCT03091777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive arm of the study
Study NCT02914821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated tax via 3 cent per ounce price increase
Description: For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
Study NCT00401895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS created with 8 or 10 mm covered stent
Description: creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
Study NCT04025671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Spray Naloxone
Description: Nasal spray naloxone device.
Study NCT04025671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Naloxone
Description: A vial of simulated naloxone and syringe with attached needle.
Study NCT04025671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Improvised Nasal Atomizer
Description: A naloxone bristoject dose and nasal atomizer device.
Study NCT00236951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose injection USP
Study NCT00236951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stable erythropoietin therapy
Study NCT04043780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decompression prototype splint for carpal tunnel syndrome
Description: This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
Study NCT04043780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard splint for carpal tunnel syndrome
Description: This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
Study NCT00706069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine oral
Description: Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
Study NCT00706069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
Study NCT03498664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap for mucosectomy
Description: endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
Study NCT03498664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard snare for polypectomy
Description: endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
Study NCT04411862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidyl Choline
Description: 2.1 g Phosphatidylcholine daily in addition to lifestyle modification
Study NCT04411862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification and health education by Clinical Pharmacist
Study NCT04411862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Lifestyle modification and health education by Clinical Pharmacist
Study NCT01631955 — intervention group
Intervention type: DRUG
Intervention: Ciprobay
Description: Ciprobay (250mg, bid, oral)
Study NCT02267642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H
Description: monoclonal antibody
Study NCT04304157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
Study NCT01662414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: 1 sachect (10 g) 2times/ day
Study NCT01662414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy protein
Description: 1 sachect (10g) 2times/day
Study NCT03099070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress
Description: Trier Social Stress Test
Study NCT03099070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 12-hour fasting prior to study visit
Study NCT00938964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine versus placebo infusion for 48 hours
Study NCT00938964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lidocaine versus placebo infusion for 48 hours
Study NCT02070471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02070471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose A
Description: LC28-0126 Dose A
Study NCT02070471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose B
Description: LC28-0126 Dose B
Study NCT02070471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126 Dose C
Description: LC28-0126 Dose C
Study NCT02436655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical aortic valve replacement
Description: open heart aortic valve replacement
Study NCT03699384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
Study NCT01423890 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: ONCOTYPEDX Test
Description: Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
Study NCT04380025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Oral Mirtogenol
Description: The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
Study NCT03699384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erenumab
Description: Subcutaneous injection of 140 mg erenumab.
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab
Description: Subcutaneous injection of 140 mg erenumab.
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of saline placebo.
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin gene-related peptide
Description: Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitonin gene-related peptide
Description: Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Oral intake of 200 mg cilostazol.
Study NCT04452929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol
Description: Oral intake of 200 mg cilostazol.
Study NCT03891160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D model of heart
Description: To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
Study NCT03654742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Description: removal of tonsil tissue as described in the study arms
Study NCT02724878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02724878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Study NCT01175538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
Study NCT04380025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of oral Dietary supplement
Description: This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
Study NCT01175538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: lactulose will be used in 30-60ml/day
Study NCT02795572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 100 mcg oral once daily
Study NCT02795572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
Study NCT03300011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: PTCA or PCI
Study NCT02632968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pinhole surgery with and without buttons
Study NCT01920334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem CR 12.5mg
Description: Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
Study NCT01920334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
Study NCT03849547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App Balance training
Description: Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program.
Study NCT03849547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Balance training
Description: Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics.
Study NCT01442376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
Study NCT01442376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
Study NCT01442376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
Study NCT02841631 — intervention group
Intervention type: GENETIC
Intervention: HPV status and typing of tissue
Description: HPV status and typing of tissue
Study NCT03193385 — intervention group
Intervention type: PROCEDURE
Intervention: closed reduction
Description: Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
Study NCT01657942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MR Guided Focused Ultrasound
Description: ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
Study NCT01442376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ondansetron
Study NCT01442376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Palonosetron
Study NCT00989950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana patch 10-30 mg administered once daily for 9hr
Study NCT00989950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana 10-30 mg worn once daily for 10 hr wear
Study NCT00989950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana 10-30 mg worn once daily for 11 hr
Study NCT00989950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Daytrana 10-30 mg worn once daily for 12 hrs
Study NCT02672267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
Study NCT02672267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's Solution
Study NCT01674387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
Study NCT01674387 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: comprehensive treatment
Description: Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
Study NCT02325180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Study NCT02325180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Study NCT02333123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
Study NCT02333123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Aspirin)
Description: Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
Study NCT03453554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Notebook app
Description: Training in use of Digital Memory Notebook app
Study NCT03453554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Notebook app
Description: Training in use of Digital Memory Notebook app
Study NCT03453554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Home Prompting
Description: Smart-home sensor based activity-aware prompting to support digital memory notebook app use
Study NCT01150422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative follow-up
Description: After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
Study NCT00945490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: Single intraprostatic injection of 2.5 mg NX-1207
Study NCT00945490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic injection of placebo
Study NCT02659462 — intervention group
Intervention type: OTHER
Intervention: Cardio Pulmonary Exercise Testing
Description: Cardio Pulmonary Exercise Testing
Study NCT01441349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IP chemotherapy
Description: Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days
Study NCT01441349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP chemotherapy plus simvastatin
Description: * Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1
Study NCT03157115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinocardiography
Description: This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group.
Study NCT03157115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinocardiography
Description: This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group.
Study NCT03053856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
Study NCT03053856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curative resection
Description: Neoadjuvant concurrent chemoradiotherapy followed by curative resection
Study NCT03053856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant concurrent chemoradiotherapy
Description: RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
Study NCT03053856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 once weekly
Study NCT03053856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50mg/m2 once weekly
Study NCT04695041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050/ Placebo
Description: Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
Study NCT03976323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion